'Newly dx cml' diaporamas de présentation

Interest in Topics Related to the Treatment of Patients with CML (Percent Responding 9 or 10)

Interest in Topics Related to the Treatment of Patients with CML (Percent Responding 9 or 10). Efficacy and tolerability of TKIs*. 42%. TKI-refractory CML. 39%. Sequencing of TKIs. 38%. New agents/regimens. 38%. Monitoring patients during therapy. 36%. Resistance mutations in BCR-ABL.

379 views • 25 slides